HCPCS Level II code J0586 denotes an injectable dose of abobotulinumtoxinA measured as 5 units per billing increment. This code captures administration of a widely used botulinum toxin formulation for neuromuscular spasticity, focal dystonias, and select aesthetic indications. Nationally, accurate use of J0586 matters for consistent clinical documentation, inventory tracking, and payer adjudication across outpatient and office-based procedures.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of clinical context and billing intent, an overview of payer coverage considerations, common modifier usage (listed separately), and benchmarking insights where available. The publication outlines reimbursement benchmarks, billing pitfalls, and recent policy updates affecting administration of abobotulinumtoxinA.

This summary serves clinicians, practice managers, and revenue cycle professionals seeking a national-level reference on coding and billing for abobotulinumtoxinA injections. Data not available in the input is noted where applicable; the content focuses on code definition, service setting, and what readers can expect to learn about coverage and billing practices.